BMRN Logo

BioMarin Pharmaceutical Inc. (BMRN) 

NASDAQ
Market Cap
$12.55B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
467 of 776
Rank in Industry
246 of 433

Largest Insider Buys in Sector

BMRN Stock Price History Chart

BMRN Stock Performance

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. …

Insider Activity of BioMarin Pharmaceutical Inc.

Over the last 12 months, insiders at BioMarin Pharmaceutical Inc. have bought $0 and sold $23.82M worth of BioMarin Pharmaceutical Inc. stock.

On average, over the past 5 years, insiders at BioMarin Pharmaceutical Inc. have bought $658,092 and sold $25.82M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 3,625 shares for transaction amount of $314,469 was made by Alles Mark J (director) on 2022‑10‑31.

List of Insider Buy and Sell Transactions, BioMarin Pharmaceutical Inc.

2024-08-13SaleGVP, Chief Accounting Officer
714
0.0004%
$90.00$64,2600.00%
2024-05-30SaleEVP, Chief Financial Officer
5,000
0.0027%
$75.19$375,950+12.73%
2024-05-28SaleEVP, Chief Legal Officer
40,850
0.0215%
$74.51$3.04M+12.62%
2024-05-10Saledirector
20,000
0.0105%
$81.14$1.62M-0.40%
2024-05-09Saledirector
20,000
0.0105%
$81.62$1.63M-1.16%
2024-05-02SaleEVP, Chief Commercial Officer
5,000
0.0026%
$82.91$414,550-2.44%
2024-05-02SaleEVP, Chief Legal Officer
1,850
0.001%
$85.01$157,269-2.44%
2024-04-12Saledirector
20,000
0.0104%
$91.26$1.83M-10.61%
2024-04-11Saledirector
20,000
0.0105%
$90.99$1.82M-9.79%
2024-04-10SaleGVP, Chief Accounting Officer
2,286
0.0012%
$90.00$205,740-8.46%
2024-03-28SaleEVP, Chief Legal Officer
24,602
0.0132%
$88.34$2.17M-4.39%
2024-03-06Saledirector
1,000
0.0005%
$86.71$86,713-3.09%
2024-03-05Saledirector
1,000
0.0005%
$85.51$85,510-2.27%
2024-03-05SalePresident, Worldwide R&D
35,341
0.0186%
$85.18$3.01M-2.27%
2024-03-05SaleEVP, Chief Commercial Officer
4,000
0.0021%
$87.07$348,280-2.27%
2024-02-27Saledirector
1,000
0.0005%
$90.35$90,350-7.15%
2024-02-09Saledirector
15,000
0.0078%
$88.28$1.32M-4.40%
2024-02-08Saledirector
15,000
0.0079%
$89.77$1.35M-4.04%
2024-01-10Saledirector
10,000
0.0054%
$96.38$963,800-10.86%
2024-01-09Saledirector
10,000
0.0054%
$98.19$981,900-10.91%

Insider Historical Profitability

19.67%
BIENAIME JEAN JACQUESdirector
474994
0.2492%
$65.8626321+29.88%
Mueller BrianEVP, Chief Financial Officer
72159
0.0379%
$65.86232+36.78%
Davis George EricEVP, Chief Legal Officer
56157
0.0295%
$65.86473+5.04%
MEIER RICHARD A
104032
0.0546%
$65.8649+42.46%
PRICE FREDRIC DChief Executive Officer
79285
0.0416%
$65.8610<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
PRIMECAP Management Co$1.63B9.8618.71M+1.63%+$26.16M1.2
The Vanguard Group$1.58B9.5418.12M+0.37%+$5.86M0.03
BlackRock$1.26B7.6314.48M-1.38%-$17.72M0.03
Dodge & Cox$1.22B7.3713.99M<0.01%-$97,820.800.71
State Street$602.23M3.636.9M+2.45%+$14.38M0.03
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.